Updated on 31 August 2026
Artificial Intelligence and Machine Learning for personalised disease treatment, prediction, prognosis
Researcher in Artificial Intelligence and Automatic Control at Sapienza University of Rome
Rome, Italy
About
For the transition to a patient-centered, personalised health system, from early diagnosis and risk prediction to cognitive rehabilitation, we provide our expertise in the design and development of clinical decision support systems based on AI and ML techniques (supervised machine learning and deep reinforcement learning). With the assistance of national and international clinical partners, the AI methodologies have been thoroughly explored and put to use in prior national-funded and EU-funded initiatives.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
Clinical Studies for Horizon Europe Cluster Health 2027
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Juan Abolafia
Head EU office at Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer
Barcelona, Spain
Project cooperation
Smart Workflow Automation for Clinical Trial Management
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
George Nikolaidis
CEO at Ergobyte Informatics S.A.
Thessaloniki, Greece
Project cooperation
GCS HUGO, in integrated academic health network of University Hospitals in Western France
- Partner seeks Consortium/Coordinator
- Consortium/Coordinator seeks Partners
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Clinical trials: HORIZON-HLTH-2027-01-DISEASE-10 Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
François Sieber
European Coordinator - GCS HUGO at GCS HUGO
Angers, France